In an effort to provide you with timely market feedback from ASCO 2014, OBR and MDoutlook are pleased to share results from MDoutlook’s OncoPolls™ from the meeting. This first report explored presentations in colorectal cancers (CRC).
Geographic Distribution of Respondents
Attendance at 2014 ASCO Annual Meeting
Survey Participants’ GI Cancer Patient Flow: Average Over 13 Cases Each Month
* Survey Participants = Medical Oncologists with an identified clinical interest in gastrointestinal cancers
Inclusion of Bevacizumab or Cetuximab with 1st Line Chemotherapy for KRASWT mCRC: Impact of the CALGB/SWOG 80405 Trial
Adjuvant Chemotherapy for Localized Rectal Cancer: Impact of the ADORE Trial Results
Conclusions: Impact of ASCO 2014 on Clinical Practices for Colorectal Cancers
For a more detailed analysis report, please click here to download the full report.
Submitted by Robert Stephan, Sr. Director Medical Services and Strategy; Jessica Harnisch, Assoc. Global Medical Analyst; Justin Boag, Consultant; and Jan Heybroek, President MDoutlook.
You must be logged in to post a comment